Richard Batrla

Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data.

Journal: Journal of managed care & specialty pharmacy

Published: July 24, 2025

Real-world diagnostic, referral, and treatment patterns in early Alzheimer's disease among community-based practices in the United States.

Journal: Journal of Alzheimer's disease : JAD

Published: November 29, 2024

Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States.

Journal: The journal of prevention of Alzheimer's disease

Published: July 24, 2024

Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.

Journal: Nature reviews. Neurology

Published: May 16, 2024

Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: April 25, 2024

Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: April 24, 2024

The age-specific comorbidity burden of mild cognitive impairment: a US claims database study.

Journal: Alzheimer's research & therapy

Published: July 19, 2023

Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.

Journal: Neuron

Published: December 17, 2022

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: October 23, 2020

Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: June 29, 2020

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: May 08, 2020

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease .

Journal: Dialogues in clinical neuroscience

Published: October 23, 2019

Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data.

Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data.

Real-world diagnostic, referral, and treatment patterns in early Alzheimer's disease among community-based practices in the United States.

Real-world diagnostic, referral, and treatment patterns in early Alzheimer's disease among community-based practices in the United States.

Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States.

Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States.

Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.

Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.

Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.

Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.

Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.

Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.

The age-specific comorbidity burden of mild cognitive impairment: a US claims database study.

The age-specific comorbidity burden of mild cognitive impairment: a US claims database study.

Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.

Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau.

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau.

Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults.

Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults.

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease .

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease .

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease .

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease .